$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000109355715000354 Filed on November 04, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$130.8M	$105.2M	$69.00M
YoY Change	55.16%	52.46%	60.84%
Cost Of Revenue	$39.60M	$30.50M	$21.80M
YoY Change	59.04%	39.91%	42.48%
Gross Profit	$91.20M	$74.70M	$47.20M
YoY Change	53.54%	58.26%	71.01%
Gross Profit Margin	69.72%	71.01%	68.41%
Selling, General & Admin	$61.10M	$52.30M	$33.70M
YoY Change	68.78%	55.19%	56.02%
% of Gross Profit	67.0%	70.01%	71.4%
Research & Development	$28.50M	$64.80M	$18.50M
YoY Change	31.94%	250.27%	56.78%
% of Gross Profit	31.25%	86.75%	39.19%
Depreciation & Amortization	$3.100M	$2.700M	$2.200M
YoY Change	29.17%	22.73%	29.41%
% of Gross Profit	3.4%	3.61%	4.66%
Operating Expenses	$89.60M	$117.1M	$52.20M
YoY Change	55.02%	124.33%	56.29%
Operating Profit	$1.600M	-$42.40M	-$5.000M
YoY Change	0.0%	748.0%	-13.79%
Interest Expense	$0.00	$100.0K	$200.0K
YoY Change	-100.0%	-50.0%	0.0%
% of Operating Profit	0.0%
Other Income/Expense, Net
YoY Change
Pretax Income	$1.600M	-$42.50M	-$5.200M
YoY Change	14.29%	717.31%	-13.33%
Income Tax	$100.0K	$0.00	$0.00
% Of Pretax Income	6.25%
Net Earnings	$1.500M	-$42.50M	-$5.200M
YoY Change	15.38%	717.31%	-13.33%
Net Earnings / Revenue	1.15%	-40.4%	-7.54%
Basic Earnings Per Share
Diluted Earnings Per Share	$18.38K	-$528.0K	-$68.60K
COMMON SHARES
Basic Shares Outstanding	81.29M shares	80.50M shares	75.80M shares
Diluted Shares Outstanding		80.50M shares	76.10M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$115.2M	$113.3M	$74.90M
YoY Change	37.8%	51.27%	57.35%
Cash & Equivalents	$86.10M	$85.30M	$63.20M
Short-Term Investments	$29.10M	$28.00M	$11.70M
Other Short-Term Assets	$6.800M	$4.000M	$2.800M
YoY Change	74.36%	42.86%	12.0%
Inventory	$35.20M	$30.60M	$14.30M
Prepaid Expenses
Receivables	$74.10M	$55.80M	$31.40M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$231.3M	$203.7M	$123.4M
YoY Change	58.53%	65.07%	51.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$54.70M	$46.60M	$28.00M
YoY Change	75.32%	66.43%	42.13%
Goodwill	$3.700M	$3.700M	$3.200M
YoY Change	15.63%	15.63%	0.0%
Intangibles	$2.200M	$2.400M	$3.100M
YoY Change	-18.52%	-22.58%	-16.22%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$300.0K	$700.0K
YoY Change	-83.33%	-57.14%	-12.5%
Total Long-Term Assets	$60.70M	$53.00M	$36.00M
YoY Change	56.85%	47.22%	26.76%
TOTAL ASSETS
Total Short-Term Assets	$231.3M	$203.7M	$123.4M
Total Long-Term Assets	$60.70M	$53.00M	$36.00M
Total Assets	$292.0M	$256.7M	$159.4M
YoY Change	58.18%	61.04%	44.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.00M	$16.70M	$7.900M
YoY Change	91.92%	111.39%	107.89%
Accrued Expenses	$44.80M	$38.00M	$29.80M
YoY Change	61.73%	27.52%	40.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.300M	$2.500M	$2.300M
YoY Change	0.0%	8.7%	27.78%
Total Short-Term Liabilities	$66.90M	$58.80M	$40.60M
YoY Change	64.78%	44.83%	48.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$400.0K	$2.900M
YoY Change	-100.0%	-86.21%	-44.23%
Other Long-Term Liabilities	$3.900M	$4.200M	$900.0K
YoY Change	160.0%	366.67%	-67.86%
Total Long-Term Liabilities	$3.900M	$4.200M	$900.0K
YoY Change	160.0%	366.67%	-67.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$66.90M	$58.80M	$40.60M
Total Long-Term Liabilities	$3.900M	$4.200M	$900.0K
Total Liabilities	$70.80M	$63.40M	$44.40M
YoY Change	59.46%	42.79%	25.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$555.4M	-$556.9M	-$499.1M
YoY Change	11.57%	11.58%	5.56%
Common Stock	$776.8M	$750.4M	$614.1M
YoY Change	21.76%	22.2%	12.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$221.2M	$193.3M	$115.0M
YoY Change
Total Liabilities & Shareholders Equity	$292.0M	$256.7M	$159.4M
YoY Change	58.18%	61.04%	44.78%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	$1.500M	-$42.50M	-$5.200M
YoY Change	15.38%	717.31%	-13.33%
Depreciation, Depletion And Amortization	$3.100M	$2.700M	$2.200M
YoY Change	29.17%	22.73%	29.41%
Cash From Operating Activities	$11.30M	$17.90M	$11.40M
YoY Change	34.52%	57.02%	612.5%
INVESTING ACTIVITIES
Capital Expenditures	-$11.60M	-$7.400M	-$3.700M
YoY Change	152.17%	100.0%	68.18%
Acquisitions
YoY Change
Other Investing Activities	-$1.100M	$1.700M	-$100.0K
YoY Change	1000.0%	-1800.0%	-102.56%
Cash From Investing Activities	-$12.70M	-$5.700M	-$3.800M
YoY Change	170.21%	50.0%	-323.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.200M	5.400M	6.100M
YoY Change	-55.1%	-11.48%	221.05%
NET CHANGE
Cash From Operating Activities	11.30M	17.90M	11.40M
Cash From Investing Activities	-12.70M	-5.700M	-3.800M
Cash From Financing Activities	2.200M	5.400M	6.100M
Net Change In Cash	800.0K	17.60M	13.70M
YoY Change	-90.7%	28.47%	163.46%
FREE CASH FLOW
Cash From Operating Activities	$11.30M	$17.90M	$11.40M
Capital Expenditures	-$11.60M	-$7.400M	-$3.700M
Free Cash Flow	$22.90M	$25.30M	$15.10M
YoY Change	76.15%	67.55%	297.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	81294938	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
	dei	Trading Symbol TradingSymbol	DXCM
CY2014Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	42400000	USD
CY2015Q3	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	55800000	USD
CY2014Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1600000	USD
CY2015Q3	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	2500000	USD
CY2014Q4	dxcm	Clinical Trials ClinicalTrials	400000	USD
CY2015Q3	dxcm	Clinical Trials ClinicalTrials	400000	USD
CY2012Q4	dxcm	Debt Instrument Basis Spread On Treasury Variable Rate DebtInstrumentBasisSpreadOnTreasuryVariableRate	0.0694
CY2014Q3	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	0	USD
	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	600000	USD
CY2015Q3	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	0	USD
	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	0	USD
CY2014Q3	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1100000	USD
	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	2100000	USD
CY2015Q3	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1000000	USD
	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1300000	USD
	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	-700000	USD
	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	0	USD
CY2014Q3	dxcm	Markto Marketon Contingent Consideration Obligation Settleablein Shares MarktoMarketonContingentConsiderationObligationSettleableinShares	-900000	USD
	dxcm	Markto Marketon Contingent Consideration Obligation Settleablein Shares MarktoMarketonContingentConsiderationObligationSettleableinShares	-700000	USD
CY2015Q3	dxcm	Markto Marketon Contingent Consideration Obligation Settleablein Shares MarktoMarketonContingentConsiderationObligationSettleableinShares	0	USD
	dxcm	Markto Marketon Contingent Consideration Obligation Settleablein Shares MarktoMarketonContingentConsiderationObligationSettleableinShares	0	USD
	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.04
	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025
CY2012Q4	dxcm	Prime Rate Plus PrimeRatePlus	0.005
	dxcm	R Dexpensethroughissuanceofcommonstock RDexpensethroughissuanceofcommonstock	0	USD
	dxcm	R Dexpensethroughissuanceofcommonstock RDexpensethroughissuanceofcommonstock	36500000	USD
	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2013	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	500000	USD
CY2014	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	2500000	USD
	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	1000000	USD
CY2013Q3	dxcm	Researchand Development Arrangement Valueof Grant ResearchandDevelopmentArrangementValueofGrant	4000000	USD
	dxcm	Sales Return Coverage Period SalesReturnCoveragePeriod	P30D
CY2012Q4	dxcm	Term Loan Advances Aggregate Amount TermLoanAdvancesAggregateAmount	7000000	USD
CY2012Q4	dxcm	Term Loan Debt TermLoanDebt	20000000	USD
CY2015Q3	dxcm	Working Capital WorkingCapital	144900000	USD
CY2014Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	20400000	USD
CY2015Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	34300000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9900000	USD
CY2015Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	16700000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-300000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-300000	USD
	us-gaap	Interest Expense InterestExpense	400000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	638000000	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	750400000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	300000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	200000	USD
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8100000	shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5800000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5800000	shares
CY2014Q4	us-gaap	Assets Assets	184600000	USD
CY2015Q3	us-gaap	Assets Assets	256700000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	145900000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	203700000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11800000	USD
CY2015Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	28000000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11800000	USD
CY2015Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	28000000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43200000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63200000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71800000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85300000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	20000000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	13500000	USD
CY2015Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	113300000	USD
CY2014Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	54300000	USD
CY2015Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	33100000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77600000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81500000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77300000	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81300000	shares
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2015Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5100000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23700000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42500000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59300000	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	21800000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	57400000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	30500000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	84000000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	21800000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	58000000	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	30500000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	84000000	USD
CY2012Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-11-01
CY2015Q3	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	15000000	USD
CY2012Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	13000000	USD
CY2012	us-gaap	Debt Issuance Costs DebtIssuanceCosts	1100000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	700000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1600000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6000000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7700000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17200000	USD
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20400000	USD
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	166200000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-300000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2015Q3	us-gaap	Goodwill Goodwill	3700000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	47200000	USD
	us-gaap	Gross Profit GrossProfit	116900000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	74700000	USD
	us-gaap	Gross Profit GrossProfit	187200000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.32
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.53
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.75
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.33
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.53
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.75
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6100000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12800000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5300000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13400000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-100000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	900000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1700000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3100000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5300000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14600000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-300000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	2800000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-700000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1000000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	100000	USD
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	300000	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	300000	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2700000	USD
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2400000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	200000	USD
	us-gaap	Interest Expense InterestExpense	600000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7400000	USD
CY2015Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17400000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	16000000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	30600000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7600000	USD
CY2015Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10700000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1000000	USD
CY2015Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2500000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	44400000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	63400000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	184600000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	256700000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40600000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	58800000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	15000000	USD
CY2015Q3	us-gaap	Long Term Debt LongTermDebt	2900000	USD
CY2015Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	600000	USD
CY2015Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2300000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16900000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14600000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12100000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38800000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15200000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	37700000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-5200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23700000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-42500000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-59100000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6100000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24400000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-42500000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-59100000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	52200000	USD
	us-gaap	Operating Expenses OperatingExpenses	140000000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	117100000	USD
CY2015Q3	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1800000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	4900000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	18800000	USD
	us-gaap	Operating Expenses OperatingExpenses	245900000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23100000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42400000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-58700000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	32600000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1200000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5300000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5200000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4300000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4700000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	11900000	USD
CY2014Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	800000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2300000	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4200000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8500000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14700000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	600000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	300000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	100000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-200000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1500000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4200000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-1800000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10300000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	35400000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11600000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21700000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3900000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16300000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9800000	USD
CY2014Q3	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1300000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3500000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31200000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46600000	USD
CY2015Q3	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	43200000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1600000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1700000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18500000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47800000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64800000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109000000	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-497800000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-556900000	USD
CY2014Q3	us-gaap	Revenues Revenues	69000000	USD
	us-gaap	Revenues Revenues	174900000	USD
CY2015Q3	us-gaap	Revenues Revenues	105200000	USD
	us-gaap	Revenues Revenues	271200000	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	67900000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	172800000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	104200000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	269900000	USD
CY2014Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2300000	USD
CY2015Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	2500000	USD
CY2014Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2300000	USD
CY2015Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	400000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33700000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	92200000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52300000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	136900000	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	13800000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	35700000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	22600000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	59200000	USD
CY2013Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	900000	USD
CY2014Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	900000	USD
CY2014Q3	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1200000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1300000	USD
CY2015Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1200000	USD
CY2015Q3	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1300000	USD
CY2014Q3	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1600000	USD
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	3800000	USD
CY2015Q3	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1900000	USD
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	4900000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	140200000	USD
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	193300000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	80500000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79200000	shares
CY2015Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	100000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76100000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75000000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80500000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79200000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75800000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74700000	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of</font><font style="font-family:inherit;font-size:10pt;"> continuous glucose monitoring (“CGM”)</font><font style="font-family:inherit;font-size:10pt;"> systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with </font><font style="font-family:inherit;font-size:10pt;">U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;"> requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical trial expenses, allowance for bad debt, refunds and rebates, including pharmacy rebates and share-based compensation expense. </font></div></div>

Files In Submission

Name	View Source	Status
0001093557-15-000354-index-headers.html	Edgar Link	pending
0001093557-15-000354-index.html	Edgar Link	pending
0001093557-15-000354.txt	Edgar Link	pending
0001093557-15-000354-xbrl.zip	Edgar Link	pending
dxcm-09302015x10q.htm	Edgar Link	pending
dxcm-20150930.xml	Edgar Link	completed
dxcm-20150930.xsd	Edgar Link	pending
dxcm-20150930_cal.xml	Edgar Link	unprocessable
dxcm-20150930_def.xml	Edgar Link	unprocessable
dxcm-20150930_lab.xml	Edgar Link	unprocessable
dxcm-20150930_pre.xml	Edgar Link	unprocessable
dxcm09302015exhibit3101.htm	Edgar Link	pending
dxcm09302015exhibit3102.htm	Edgar Link	pending
dxcm09302015exhibit3201.htm	Edgar Link	pending
dxcm09302015exhibit3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gls-dxcmcollaborationagree.htm	Edgar Link	pending
image2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2015 Q4 Form 10-Q Financial Statement

#000109355715000354 Filed on November 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2015 Q4 Form 10-Q Financial Statement

#000109355715000354 Filed on November 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm